European Journal of Nuclear Medicine and Molecular Imaging provides a platform for exchanging clinical and scientific information within nuclear medicine and allied professions.
The European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) covers a broad scope of (molecular) imaging, radiopharmaceutical therapy, image guided therapy, artificial intelligence, among others, and spans the entire spectrum of preclinical, translational, and clinical research.
In this collection, we aim to capture a snapshot of the global state-of-art of translational research with nanomaterials, nanobodies, and protein scaffolds (affibodies, knottin, fibronectin, DARPin, among others). All original work that falls into the scope of EJNMMI and the theme of this collection will be considered and undergo rigorous peer review. Review articles are also welcome; however, they must be systematic rather than narrative.
Submit your manuscript to this collection through the participating journal.
-
Jessica C. Hsu, PhD, University of Wisconsin - Madison, USA
Dr. Jessica Hsu received a BS in Nuclear Engineering from the University of Illinois at Urbana-Champaign in 2013 and a PhD in Bioengineering from the University of Pennsylvania in 2021. She is currently a postdoctoral fellow in the Departments of Medical Physics and Radiology at the University of Wisconsin-Madison under the mentorship of Prof. Weibo Cai. She developed nanoparticle contrast agents for X-ray imaging as part of her thesis work. Her research is now focused on developing nanomedicine platforms for imaging and treatment of kidney diseases. -
Marleen Keyaerts, PhD, Vrije Universiteit Brussel, Belgium
Marleen Keyaerts is a nuclear medicine specialist and current head of the department of nuclear medicine at Jessa Hasselt, Belgium. Even more than a medical doctor, she is a scientific researcher, with a PhD in preclinical molecular imaging and therapy, and over 10 years of experience as the team lead for translational and clinical research at Vrije Universiteit Brussel and UZ Brussel, using single domain antibody-based radiopharmaceuticals. Applications extend from HER2-expressing cancer, over immuno-oncology to cardiology and endocrinology. -
Weibo Cai, PhD, University of Wisconsin - Madison, USA
Dr. Cai is Vilas Distinguished Achievement Professor of Radiology/Medical Physics/MSE/Pharmaceutical Sciences at University of Wisconsin - Madison, USA. He received PhD in Chemistry from UCSD in 2004. Dr. Cai’s research at UW-Madison (http://mi.wisc.edu/) focuses on molecular imaging, nanobiotechnology, and theranostics. He has authored >400 articles (h-index: 106), edited 3 books, given >360 talks, and received many awards (e.g. FAIMBE, FSNMMI, FRSC, ACS Research Scholar, SNMMI Michael J. Welch Award, JNB Trailblazer Award). He is EIC of Journal of Nanobiotechnology (IF 10.6) and AE of EJNMMI (IF 8.6). Dr. Cai’s trainees have received >150 a
Showing 1-3 of 3 articles
